Meta-analysis of 12 studies reports chemotherapy-induced nausea and vomiting prevalence and risk factors in breast cancer patients
Nearly Half of Breast Cancer Patients Face This Rough Side Effect
This meta-analysis pooled data from 12 studies involving breast cancer patients undergoing chemotherapy to assess the prevalence of chemothe…
Knowing who is most likely to get sick from chemo allows doctors to step in before nausea takes over a patient's life.
Electronic antiemetic device plus ondansetron improved delayed CINV response in 126 cancer patients
A Wearable Buzz on Your Wrist May Ease Chemo Nausea
This single-centre randomized controlled trial enrolled 126 cancer patients receiving moderately or highly emetogenic chemotherapy.
A small device targeting an old acupressure point may give real relief from the days-long nausea that chemo drugs leave behind.
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting
FDA approves a new intravenous drug to help prevent nausea and vomiting from chemotherapy
The FDA has approved Focinvez, a substance P/NK1 receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated…
FDA approves new IV drug to prevent severe nausea and vomiting from chemotherapy in adults and children 6 months and older.
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
Questions about Chemotherapy-Induced Nausea and Vomiting
What risk factors are associated with chemotherapy-induced nausea and vomiting in breast cancer?
Key risk factors for CINV in breast cancer include younger age (≤45 years), history of motion sickness, and multiple chemotherapy cycles (≥3).
Full answer →Can Focinvez prevent chemotherapy-induced nausea and vomiting in cancer patients?
Yes, Focinvez (fosaprepitant) is FDA-approved to prevent chemotherapy-induced nausea and vomiting when used with other antiemetics.
Full answer →How do 5-HT3 antagonists compare to dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting?
5-HT3 antagonists and dexamethasone are both effective for CINV, but adding a 5-HT3 antagonist to dexamethasone improves outcomes; guidelines recommend using them together with other agents for highly emetogenic chemotherapy.
Full answer →How common is chemotherapy-induced nausea and vomiting in breast cancer patients?
About 48% of breast cancer patients experience chemotherapy-induced nausea and vomiting, with higher risk in younger patients and those with motion sickness history.
Full answer →